Algonquin Power has approved and declared the following common and preferred share dividends: 18.08c per common share, payable on October 14 to shareholders of record on September 29 for the period from July 1 to September 30; shareholders receiving dividends in cash can elect to receive the dividend in Canadian dollars in the amount of C$0.2312. C$0.32263 per preferred share, Series A, payable in cash on October 3 to preferred share, Series A holders of record on September 15 for the period from June 30 to, but excluding, September 30. C$0.31819 per preferred share, Series D, payable in cash on October 3 to preferred share, Series D holders of record on September 15 for the period from June 30 to, but excluding, September 30. . Plan Shares will be acquired by way of a treasury purchase at the average market price as defined in the Plan less a 3% discount.

Agios Pharmaceuticals announced that data from the core period of the open-label, Phase 2 study of PYRUKYND in adults with non-transfusion-dependent alpha- or beta-thalassemia were published on August 11, 2022, in The Lancet. Data from this study were previously presented at the 2021 European Hematology Association Annual Congress. PYRUKYND is a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase enzymes. "Consistent with previously reported findings, the data reported today underscore the potential of PK activation to improve hallmarks of alpha- and beta-thalassemia, including hemolysis and ineffective erythropoiesis," said Kevin Kuo, M.D., hematologist at University of Toronto, Toronto General Hospital, and an investigator in the study. "Thalassemia is a rare, debilitating lifelong blood disorder characterized by severe complications, with no treatment options for those with alpha-thalassemia and limited options for those with beta-thalassemia. These data demonstrate the potential clinical benefits of mitapivat for a broad spectrum of thalassemia patients and support its continued investigation in pivotal trials."

In a regulatory filing, Quanterix director Sarah Hlavinka disclosed the purchase of 10.1K common shares of the company on August 11 at a price of $9.89 per share. Shares of Quanterix rose 18.7% today following insider buying activity yesterday evening and are up another 6.2% afterhours.

Hologic (HOLX) announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a 2018 district court ruling that barred Minerva (NERV) from challenging the validity of the patent rights it assigned to Hologic. "We are pleased that the U.S. Court of Appeals has once again ruled in our favor. This important decision confirms that good faith and fair dealing apply to transactions involving patents and provides greater certainty for companies like Hologic who acquire innovative technologies in order to provide physicians and their patients with the latest solutions," said Essex Mitchell, President of Hologic's GYN Surgical Solutions Division. In 2015, Hologic sued Minerva alleging that the company's endometrial ablation system infringes patents acquired by Hologic through its 2004 purchase of Novacept, the developer of the NovaSure endometrial ablation system for abnormal uterine bleeding. The suit alleged that four years after Hologic's acquisition of Novacept, a former Novacept executive founded Minerva and developed and commercialized an endometrial ablation device using the patented technology that was acquired by Hologic in the Novacept transaction. In 2018, a Delaware district court found Minerva liable for patent infringement and barred the company's invalidity defenses under assignor estoppel. A jury awarded Hologic $4.8M in damages for Minerva's infringement. This decision by the U.S. Court of Appeals is the latest decision in Hologic's favor on this matter. In 2019, the Federal Circuit affirmed the district court ruling on infringement and assignor estoppel. In 2021, the U.S. Supreme Court clarified the scope of assignor estoppel and, on remand, the Federal Circuit again ruled in Hologic's favor, holding that Minerva's invalidity challenge contradicted multiple representations made by the Novacept executive, including in assigning the patent. With the Federal Circuit decision, Minerva must now pay Hologic more than $7M in damages, which includes the $4.8M in damages originally awarded plus post-trial damages and interest.

Vasta Platform announced the beginning of a transition period of its CFO. From today until September 15, CFO Bruno Giardino will transfer his activities to Cesar Augusto Silva, after which Giardino will be dedicated to personal projects. After September, 15, Silva will serve as Vasta's new CFO, and Mario Ghio Junior, Vasta's CEO, will assume the responsibilities of Investor Relations Officer as well. Silva is an economist and accountant with an MBA in business administration, and has more than 25 years' experience in financial management and controllership. Silva has been working at the Cogna Group as Controllership Director since 2016, having actively participated in Vasta's IPO process with Nasdaq.